VLDLR Antibody



PACO20858

Product Information

Size:

50ul

Reactivity:

Human, Mouse, Rat

Source:

Rabbit

Isotype:

lgG

Applications:

ELISA, IHC

Recommended dilutions:

ELISA:1:2000-1:5000, IHC:1:25-1:100

Protein Background:

Anti-apoptotic protein which acts by inhibiting the activities of CASP3, CASP7 and CASP9. Can inhibit the autocleavage of pro-CASP9 and cleavage of pro-CASP3 by CASP9. Capable of inhibiting CASP9 autoproteolysis at 'Asp-315' and decreasing the rate of auto proteolysis at 'Asp-330'. Acts as a mediator of neuronal survival in pathological conditions. Prevents motor-neuron apoptosis induced by a variety of signals. Possible role in the prevention of spinal muscular atrophy that seems to be caused by inappropriate persistence of motor-neuron apoptosis: mutated or deleted forms of NAIP have been found in individuals with severe spinal muscular atrophy. Acts as a sensor component of the NLRC4 inflammasome that specifically recognizes and binds needle protein Cprl from pathogenic bacteria C. violaceum. Association of pathogenic bacteria proteins drives in turn drive assembly and activation of the NLRC4 inflammasome, promoting caspase-1 activation, cytokine production and macrophage pyroptosis.

Gene ID:

VLDLR

Uniprot

P98155

Synonyms:

very low density lipoprotein receptor


Immunogen:

Synthetic peptide of human VLDLR.

Storage:

-20° C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol

Product Images



The image on the left is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using PACO20858(VLDLR Antibody) at dilution 1/35, on the right is treated with synthetic peptide. (Original magnification: x—200).

The image on the left is immunohistochemistry of paraffin-embedded Human liver cancer tissue using PACO20858(VLDLR Antibody) at dilution 1/35, on the right is treated with synthetic peptide. (Original magnification: x—200).